XML 24 R13.htm IDEA: XBRL DOCUMENT v3.22.2

Accrued Liabilities

6 Months Ended

Jun. 30, 2022

Payables and Accruals [Abstract]

Accrued Liabilities

Accrued Liabilities

As of June 30, 2022 and December 31, 2021, the Company's accrued liabilities balance consists of the following (in thousands):

 

			June 30, 2022						December 31, 2021
Accrued clinical trial expenses			$	17,019					$	19,410
Accrued professional fees			11,336						10,678
Accrued technical operation expenses			4,816						6,187
Accrued royalty payable			7,182						6,655
Accrued interest payable			2,175						2,175
Accrued sales allowances and related costs			11,470						8,275
Deferred consideration			3,459						4,883
Accrued construction costs			105						551
Other accrued liabilities			1,208						1,851
			$	58,770					$	60,665

X

- Definition

The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(a),20,24)
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

+ Details

Name:	us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_PayablesAndAccrualsAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration